Roche Holding AG (RHHBY)
35.44
+0.15
(+0.43%)
USD |
OTCM |
Nov 22, 16:24
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 225.91B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 9.44% |
| Valuation | |
| PE Ratio | 19.20 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.365 |
| Price to Book Value | 7.017 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.349 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.19 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 40.92% |
Profile
| Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. |
| URL | https://www.roche.com |
| Investor Relations URL | https://www.roche.com/investors.htm |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Jul. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2024 |
Ratings
Profile
| Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. |
| URL | https://www.roche.com |
| Investor Relations URL | https://www.roche.com/investors.htm |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Jul. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2024 |